An evaluation of voclosporin for the treatment of lupus nephritis

  title={An evaluation of voclosporin for the treatment of lupus nephritis},
  author={Fang En Sin and David A. Isenberg},
  journal={Expert Opinion on Pharmacotherapy},
  pages={1613 - 1621}
  • F. Sin, D. Isenberg
  • Published 12 September 2018
  • Medicine
  • Expert Opinion on Pharmacotherapy
ABSTRACT Introduction: Lupus nephritis (LN) is associated with significant morbidity and mortality. Current treatment outcomes remain suboptimal. No disease modifying medications are licensed for the treatment of LN. Voclosporin, a novel calcineurin inhibitor, has been investigated as induction therapy in LN in combination with myocophenolate mofetil (MMF) and a glucocorticoid (GC). Two phase II trials of voclosporin were the first trials of a potential treatment of active LN that met their… 
Individualizing Therapy in Lupus Nephritis
Lupus nephritis: challenges and progress.
PURPOSE OF REVIEW The management of lupus nephritis remains unsatisfactory due to insufficiently effective treatment regimens and the dearth of reliable predictors of disease onset or progression to
A glimpse into the future of systemic lupus erythematosus
This viewpoint article on a forecast of clinically meaningful changes in the management of systemic lupus erythematosus (SLE) in the next 10 years is based on a review of the current state of the
Protecting the kidney in systemic lupus erythematosus: from diagnosis to therapy
Developments in the understanding of tubulointerstitial injury and repair are yielding new strategies for preserving renal function and preventing fibrosis, and improvements in risk assessment using genetic or transcriptomic biomarkers could enable the design of clinical trials to prevent LN onset and progression.
A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies
Recent advances in the understanding of disease pathogenesis in lupus nephritis are discussed in the context of potential emerging therapies.
Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues
This review is to answer some important questions that may arise from its use in daily clinical practice, and to propose a paradigm based on the use of methylprednisolone pulses followed by medium-low doses and a rapid decrease of prednisone.
Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies
  • J. Wenzel
  • Biology, Medicine
    Nature Reviews Rheumatology
  • 2019
Insights into the cellular and molecular pathogenesis of cutaneous lupus erythematosus have triggered the development of new therapeutic strategies, including targeted treatment strategies that mainly target type I interferon-producing cells and their pathways.
Calcineurin inhibitor (CNI)‐associated skin cancers: New insights on exploring mechanisms by which CNIs downregulate DNA repair machinery
The use of the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus remains a cornerstone in post‐transplantation immunosuppression, and it is unknown which isoform regulates UV‐induced DNA repair, which is the focus of this review.
2021 FDA TIDES (Peptides and Oligonucleotides) Harvest
In this review, the approved TIDE-based drugs are analyzed on the basis of their chemical structure, medical target, mode of action, administration route, and adverse effects.


AB0419 Aurion Study: Preliminary Results of Voclosporin in Lupus Nephritis
Preliminary data from this this pilot study indicates that MTT using VCS, in combination with MMF and steroids, produced consistent reductions in proteinuria with preservation of renal function in the first 7 subjects enrolled with active LN.
Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.
Immunosuppressive treatment for proliferative lupus nephritis.
The effects of all treatment strategies on death (all causes) and ESKD were uncertain and the benefits and harms of different immunosuppressive treatments in people with biopsy-proven lupus nephritis were evaluated.
Tacrolimus use in lupus nephritis: A systematic review and meta-analysis.
Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study
Cyclosporine A was as effective as cyclophosphamide in the trial of sequential induction and maintenance treatment in patients with proliferative lupus nephritis and preserved renal function.
20 Aurion study: 24-week data of multi-target therapy with voclosporin, mmf and steroids for active lupus nephritis
The results suggest that early response to therapy of VCS in combination with MMF may predict 24 week CR in the presence of low steroids in active LN.
Thirty years of cyclophosphamide: assessing the evidence
Intravenous cyclophosphamide is the only therapy with long-term data for reduction of end-stage renal disease and as data on other therapies accumulate, however, it might no longer be considered the standard treatment for lupus nephritis.
A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years.
For patients with diffuse proliferative lupus nephritis, azathioprine or cyclosporine combined with corticosteroids demonstrated equal efficacy in the prevention of flares.
Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up
TAC is non-inferior to MMF, when combined with prednisolone, for induction therapy of active LN, and with azathioprine maintenance for 5 years, a non-significant trend of higher incidence of renal flares and renal function decline is observed with the TAC regimen.
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids.
  • R. Pepper, M. Griffith, T. Cairns
  • Medicine
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
  • 2009
This data demonstrates the efficacy of a rituximab and MMF based regime in the treatment of lupus nephritis, allowing a reduction or total withdrawal of corticosteroids.